CN113827716A - 犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 - Google Patents
犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 Download PDFInfo
- Publication number
- CN113827716A CN113827716A CN202010582683.1A CN202010582683A CN113827716A CN 113827716 A CN113827716 A CN 113827716A CN 202010582683 A CN202010582683 A CN 202010582683A CN 113827716 A CN113827716 A CN 113827716A
- Authority
- CN
- China
- Prior art keywords
- strain
- canine distemper
- canine
- distemper virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712083 Canine morbillivirus Species 0.000 title claims abstract description 177
- 229960005486 vaccine Drugs 0.000 title claims abstract description 133
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 208000000655 Distemper Diseases 0.000 claims abstract description 60
- 241000700605 Viruses Species 0.000 claims abstract description 54
- 208000014058 canine distemper Diseases 0.000 claims abstract description 54
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 230000003053 immunization Effects 0.000 claims abstract description 31
- 239000003223 protective agent Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000004108 freeze drying Methods 0.000 claims abstract description 8
- 241000701931 Canine parvovirus Species 0.000 claims description 46
- 241000125945 Protoparvovirus Species 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000012888 bovine serum Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 116
- 201000010099 disease Diseases 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
- 230000002238 attenuated effect Effects 0.000 description 32
- 238000012360 testing method Methods 0.000 description 27
- 230000005847 immunogenicity Effects 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 18
- 230000036760 body temperature Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 16
- 230000036528 appetite Effects 0.000 description 14
- 235000019789 appetite Nutrition 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 241000282465 Canis Species 0.000 description 12
- 210000001331 nose Anatomy 0.000 description 12
- 210000000683 abdominal cavity Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000007918 pathogenicity Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 230000001018 virulence Effects 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 238000013115 immunohistochemical detection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 231100000167 toxic agent Toxicity 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 101710169105 Minor spike protein Proteins 0.000 description 4
- 101710081079 Minor spike protein H Proteins 0.000 description 4
- 208000008071 Parvoviridae Infections Diseases 0.000 description 4
- 206010057343 Parvovirus infection Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18451—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
组别 | 接种用毒株 | 接种剂量 |
1 | LT90株 | 滴鼻2ml、腹腔4ml(10<sup>5.5</sup>FAID<sub>50</sub>/ml) |
2 | LT株 | 滴鼻2ml、腹腔4ml(10<sup>5.5</sup>FAID<sub>50</sub>/ml) |
3 | DMEM培养基 | 滴鼻2ml、腹腔4ml |
组分 | 疫苗1 | 疫苗2 | 疫苗3 |
LT90株抗原(FAID<sub>50</sub>)/头份 | 10<sup>2.5</sup> | 10<sup>3.5</sup> | 10<sup>5.5</sup> |
保护剂(V/V) | 50% | 50% | 50% |
组分 | 疫苗4 | 疫苗5 |
LT90株抗原(FAID<sub>50</sub>)/头份 | 10<sup>3.5</sup> | 10<sup>5.5</sup> |
JM35株抗原(FAID<sub>50</sub>)/头份 | 10<sup>5.0</sup> | 10<sup>6.0</sup> |
保护剂(V/V) | 50% | 50% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010582683.1A CN113827716A (zh) | 2020-06-23 | 2020-06-23 | 犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010582683.1A CN113827716A (zh) | 2020-06-23 | 2020-06-23 | 犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113827716A true CN113827716A (zh) | 2021-12-24 |
Family
ID=78964261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010582683.1A Pending CN113827716A (zh) | 2020-06-23 | 2020-06-23 | 犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113827716A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091490A1 (en) * | 2000-06-30 | 2011-04-21 | Nippon Zenyaku Kogyo Co., Ltd. | Novel vaccine for dog |
CN104208669A (zh) * | 2013-09-30 | 2014-12-17 | 郑州后羿制药有限公司 | 一种犬瘟热、犬细小病毒病二联疫苗及其制备方法 |
CN106399260A (zh) * | 2015-07-31 | 2017-02-15 | 北京大北农科技集团股份有限公司动物医学研究中心 | 一种犬瘟热、细小病毒病二联活疫苗及其制备方法 |
CN107320720A (zh) * | 2016-04-29 | 2017-11-07 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物、试剂盒及应用 |
CN110302374A (zh) * | 2019-08-09 | 2019-10-08 | 中国农业科学院特产研究所 | 犬用疫苗及其制备方法和应用 |
CN110368490A (zh) * | 2019-07-22 | 2019-10-25 | 齐鲁动物保健品有限公司 | 貉细小病毒性肠炎、犬瘟热二联灭活疫苗及其制备方法 |
-
2020
- 2020-06-23 CN CN202010582683.1A patent/CN113827716A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091490A1 (en) * | 2000-06-30 | 2011-04-21 | Nippon Zenyaku Kogyo Co., Ltd. | Novel vaccine for dog |
CN104208669A (zh) * | 2013-09-30 | 2014-12-17 | 郑州后羿制药有限公司 | 一种犬瘟热、犬细小病毒病二联疫苗及其制备方法 |
CN106399260A (zh) * | 2015-07-31 | 2017-02-15 | 北京大北农科技集团股份有限公司动物医学研究中心 | 一种犬瘟热、细小病毒病二联活疫苗及其制备方法 |
CN107320720A (zh) * | 2016-04-29 | 2017-11-07 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物、试剂盒及应用 |
CN110368490A (zh) * | 2019-07-22 | 2019-10-25 | 齐鲁动物保健品有限公司 | 貉细小病毒性肠炎、犬瘟热二联灭活疫苗及其制备方法 |
CN110302374A (zh) * | 2019-08-09 | 2019-10-08 | 中国农业科学院特产研究所 | 犬用疫苗及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101524532B (zh) | 单剂量猪肺炎支原体疫苗 | |
CN100354414C (zh) | 一种伪狂犬病gEˉ/gIˉ基因缺失毒株、含有该毒株的灭活疫苗及应用 | |
CN106148287B (zh) | 猪流行性腹泻病毒株及其疫苗组合物、制备方法和应用 | |
KR101656301B1 (ko) | 마이코플라즈마 보비스 백신 | |
CN112316128B (zh) | 一种犬瘟热病毒犬细小病毒犬传染性肝炎病毒三联活疫苗 | |
JP2013223511A6 (ja) | マイコプラズマ・ボビス ワクチン | |
CN113073083B (zh) | 犬细小病毒弱毒株、及其制备的疫苗组合物和应用 | |
EP3344289B1 (en) | Pestivirus vaccines for congenital tremors | |
CN107541501B (zh) | 犬细小病毒毒株、疫苗组合物及其应用 | |
CN110812474A (zh) | 猪圆环病毒2型、猪肺炎支原体、副猪嗜血杆菌三联灭活疫苗及其制备方法 | |
AU2017202354A1 (en) | Attenuated Mannheimia haemolytica vaccines and methods of making and use | |
CN112195161B (zh) | 一种犬细小病毒疫苗株、疫苗及其制备方法 | |
CN114426956A (zh) | 猫狂犬病泛白细胞减少症鼻气管炎鼻结膜炎四联灭活疫苗 | |
CN113943714A (zh) | 一种猫杯状病毒毒株及其应用 | |
CN111808826B (zh) | 猪A型塞内卡病毒SVA/CH-Fuj株及其应用 | |
CN108251382B (zh) | 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用 | |
CN115322972B (zh) | 一株h9亚型禽流感病毒分离株及其应用 | |
CN107338227B (zh) | 牛副流感病毒pbiv3-b株及其应用 | |
CN112522217B (zh) | 一种犬瘟热弱毒株及其制备的疫苗组合物和应用 | |
US20230405110A1 (en) | Canine Parvovirus | |
CN114573708B (zh) | 副鸡禽杆菌ha融合蛋白及其三聚体、制备的疫苗组合物、制备方法和应用 | |
CN107537033B (zh) | 疫苗组合物、试剂盒及其应用 | |
CN113827716A (zh) | 犬瘟热病毒弱毒株、及其制备的疫苗组合物和应用 | |
US4312947A (en) | Process for the preparation of a vaccine against panleucopenia of the cat | |
TW201731526A (zh) | 混成核心之貓科動物疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240509 Address after: No. 25, yuwenkai street, Luolong District, Luoyang City, Henan Province 471000 Applicant after: LUOYANG HUIZHONG BIOTECH Co.,Ltd. Country or region after: China Applicant after: PULIKE BIOLOGICAL ENGINEERING, Inc. Address before: 471000 No. 5 Lingbo Road, Luoyang High-tech Zone, Henan Province Applicant before: PULIKE BIOLOGICAL ENGINEERING, Inc. Country or region before: China |